Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
WATERTOWN, Mass., March 20, 2018 -- The United States Court of Appeals for the Federal Circuit (CAFC) on March 8, 2018 decided the appeal in Exergen v. Kaz, finding Exergen’s 7,787,938 patent valid and infringed by the Vicks V977 Forehead Thermometer and the Braun FHT1000 Forehead Thermometer, both supplied by Kaz USA, Inc. of Southborough, MA, a subsidiary of Helen of Troy, Ltd of Hamilton, Bermuda. The CAFC decision preserves nearly all of the $16 million in damages awarded Exergen by the January 2016 U.S. District Court of Massachusetts jury verdict.
A recognized world leader in medical and industrial non-invasive temperature technologies, Exergen has been developing and patenting its non-invasive thermometer technology for three decades. The company’s Founder and President, Francesco Pompei, Ph.D., also a Harvard research scientist, is the inventor of nearly 100 patents.
“We are grateful to the U.S. Patent System and the Federal Courts that makes it possible for small companies like Exergen to protect its breakthrough patented technology against much larger businesses,” said Dr. Pompei. “This outcome is testament to our commitment to advancing the state-of-the-art to help our customers meet today’s challenges in healthcare in thousands of hospitals and clinics nationwide, and to giving millions of moms peace of mind when caring for their children.”
Exergen’s patented award-winning TemporalScanner™ temporal artery thermometers are manufactured in Watertown, MA USA from components and materials sourced worldwide.
ABOUT EXERGEN CORPORATION
Exergen manufactures and markets two types of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers nationwide. Nearly two billion temperatures are taken each year with the TemporalScanner, more than with any other thermometer. It is used in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, #1 preference of nurses in the US, and #1 selling retail thermometer. The Exergen TemporalScanner's performance is supported by more than 70 peer-reviewed published studies covering all ages from preterm infants to geriatrics and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
Contact: Victoria Day
Rosica Public Relations
[email protected]
P: 201.843.5600
2-14 Fair Lawn Avenue
Fair Lawn, New Jersey 07410
